SynthesisInflammopharmacology2025

The efficacy, safety, and persistence of vedolizumab versus adalimumab in patients with inflammatory bowel disease: a systematic review and meta-analysis.

Zhixin Chen et al.PubMed ↗Publisher ↗

No numbers read from the abstract.